#United States #Atlanta #Viking Therapeutics #VK2735 #ObesityWeek

Viking Therapeutics' Upcoming Presentations at ObesityWeek® 2025

Viking Therapeutics, Inc., a biopharmaceutical enterprise listed on NASDAQ as VKTX, is set to highlight significant findings from its VK2735 obesity program during this year's ObesityWeek, which is scheduled to take place from November 4-7, 2025, in Atlanta, Georgia. This annual meeting, hosted by The Obesity Society, brings together healthcare professionals and researchers focused on addressing obesity and its associated comorbidities.

VK2735 is an innovative dual agonist targeting both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, designed with the intent to treat various metabolic disorders, particularly obesity. Viking Therapeutics aims to assess both subcutaneous and oral forms of VK2735 through ongoing clinical trials, making significant strides in therapeutic development.

The company's presentations at ObesityWeek will focus on two critical areas of study. The first will deliver results from an exploratory analysis of the Phase 2 VENTURE clinical trial. This trial monitored the effects of a subcutaneous VK2735 formulation over a 13-week period among obese participants. This analysis particularly investigated how VK2735 influenced occurrences of prediabetes and metabolic syndrome in the studied cohort.

The second presentation will elaborate on the current design of the pivotal Phase 3 VANQUISH-1 trial, which studies the effects of subcutaneous VK2735 in adults classified as overweight or obese, particularly those affected by weight-related health issues. This ongoing study is vital as it continues to explore the impact of VK2735 in managing obesity effectively.

In addition to the highlights at ObesityWeek, Viking Therapeutics will also feature presentations at the American Heart Association's Scientific Sessions from November 7-10, 2025, in New Orleans, Louisiana. Two key presentations are set to take place during this conference as well. One will provide insights into the ongoing Phase 3 VANQUISH-2 trial of VK2735 administered to adults with type 2 diabetes coupled with obesity or overweight conditions. The other presentation will share analysis results regarding the prevalence of cardiometabolic issues across different body mass index (BMI) categories.

Presentation Details

ObesityWeek 2025

• - Poster Presentation Title: VANQUISH-1 Study Design Phase 3 Trial of Subcutaneous VK2735 in Adults with Overweight or Obesity
• - Presenting Author: Karen Modesto, M.D., Vice President, Clinical Development, Viking Therapeutics
• - Date/Time: Wednesday, November 5, 2025, from 2:30 PM to 3:30 PM ET

• - Poster Presentation Title: Impact of Subcutaneous VK2735 on Weight, Prediabetes, and Cardiometabolic Status - The VENTURE Study
• - Presenting Author: Harold Bays, M.D., Louisville Metabolic and Atherosclerosis Research Center
• - Date/Time: Thursday, November 6, 2025, from 2:30 PM to 3:30 PM ET

AHA Scientific Sessions 2025

• - Presentation ID: Sa2063
• - Title: VANQUISH-2 Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Weekly Subcutaneous VK2735 in Obese or Overweight Adults with Type 2 Diabetes
• - Presenting Author: Karen Modesto, M.D., Vice President, Clinical Development, Viking Therapeutics
• - Date/Time: Saturday, November 8, 2025, from 10:30 AM to 11:30 AM CT

• - Presentation ID: Sa2052
• - Title: Prevalence of Cardiometabolic Conditions Across Body Mass Index Categories - The Distinct Burden of Severe (Class III) Obesity
• - Presenting Author: Saif Rathore, M.D., Ph.D., Sandbar Life Sciences
• - Date/Time: Saturday, November 8, 2025, from 2:30 PM to 3:30 PM CT

Understanding GLP-1 and Dual Agonists

The activation of GLP-1 receptors has shown promising outcomes in reducing blood glucose levels, curbing appetite, and enhancing weight loss while improving insulin sensitivity, particularly in patients with conditions like type 2 diabetes or obesity. Noteworthy therapies in this realm include semaglutide, which is marketed under the brand names Ozempic®, Rybelsus®, and Wegovy®, all of which have gained FDA approval. Recent research also explores the co-activation of GIP receptors to enhance GLP-1 receptor therapy. Tirzepatide represents a significant advancement in this area, currently approved and marketed as Mounjaro® and Zepbound®.

About Viking Therapeutics, Inc.

Viking Therapeutics is at the forefront of biopharmaceutical innovation, focusing specifically on the creation of novel therapies targeting metabolic and endocrine disorders. With a repertoire of three compounds currently undergoing clinical evaluation, the organization utilizes its metabolic expertise to foster innovative treatment solutions aimed at enhancing patients' quality of life. VK2735 is a central player in Viking’s clinical programs, standing as a dual agonist promising advancements in treating obesity. Recent Phase 1 and Phase 2 trials have underscored VK2735's encouraging safety profile and signs of clinical efficacy, emphasizing the company's commitment to developing impactful treatments. Viking is also progressing research on VK2809, a selective thyroid hormone receptor beta agonist targeting metabolic and lipid disorders. Given its potential to treat significant health issues, Viking Therapeutics is undoubtedly making meaningful contributions in the battle against obesity and related conditions.

For additional insights into Viking Therapeutics and its pioneering work in metabolic therapies, visit www.vikingtherapeutics.com.